AIkido Pharma (NASDAQ:AIKI – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Monday, Zacks.com reports. According to Zacks, “AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The company’s pipeline of therapeutics includes […]